Bellicum Pharmaceuticals Stock Price - BLCM

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Bellicum Pharmaceuticals Inc BLCM NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.04 3.64% 1.14 1.15 1.09 1.09 1.10 17:59:52
Bid Price Ask Price Spread Spread % News
1.00 1.15 0.15 13.04% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,079 851,063 $ 1.13 $ 959,751 956,317 0.78 - 6.64
Last Trade Time Type Quantity Stock Price Currency
16:40:25 average 161,066 $ 1.14 USD

Bellicum Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 52.73M 46.25M $ -98.04M -2.46 - 45.91M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Bellicum Pharmaceuticals News

Loading Messages....

Latest BLCM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BLCM Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week1.
1 Month11.40.931.1602930k0.1414.00%
3 Months2.012.040.781.3130825k-0.87-43.28%
6 Months3.654.140.781.8960641k-2.51-68.77%
1 Year6.46.640.782.7058525k-5.26-82.19%
3 Years19.723.110.787.9180581k-18.56-94.21%
5 Years24.5633.630.7810.7049501k-23.42-95.36%

Bellicum Pharmaceuticals Description

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (BPX-501) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and T cell receptors (BPX-701) to treat blood cancers and solid tumors.

Your Recent History
Bellicum P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.